Cell-based assays market set to exhibit CAGR of 8.5 percent
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
List view / Grid view
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
In this ebook, find articles exploring some of the assays used to identify the most promising COVID-19 drugs and discussing the development of a novel assay to reveal potential peptide therapeutics for cancer.
New research has shown that the cell-based assays market will grow at a CAGR of 8.1 percent between 2020 and 2025.
Researchers have developed a cell-based assay for the discovery of new IDO1 inhibitors, overcoming challenges from cell-free assays.
A team has developed nanolitre cell assays on droplet microarrays to enable pharmacodynamic monitoring in live cells.
A team has developed enterocyte-like cells from hiPSCs, which can be used to study the absorption of novel oral drugs.
Researchers have uncovered a flaw in lab models used to study the human blood-brain barrier and a potential strategy to correct the error.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.